What we know and what we would like to know about genetics and pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 63, Issue SUPPL. 161, 2009, Pages 11-16

  Durrington, H J ^a   Morrell, N W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

CELL SURFACE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOME; HUMAN; MOLECULAR GENETICS; NONSENSE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 58849094012     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01964.x     Document Type: Review

References (42)

1. Long L, Crosby A, Yang X et al. Role of ALK-5 inhibition in prevention and progression of pulmonary hypertension. Circulation 2008 (in press).
2. Sobolewski A, Rudarakanchana N, Upton PD et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet 2008 17 : 3180 90.
3. Clarke RC, Coombs CF, Hadfield G, Todd AT. On certain abnormalities, congenital and acquired of the pulmonary artery. Quart J Med 1927 21 : 51.
4. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954 30 : 195.
5. Loyd JE, Primm RK, Newman JH. Transmission of familial primary pulmonary arterial hypertension. Am Rev Respir Dis 1984 129 : 194 7.
6. Loyd JE, Butlee MG, Foroud TM et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995 152 : 93 7.
7. Nichols WC, Koller DL, Slovis B et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997 3 : 277 80.
8. Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000 26 : 81 4.
9. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000 67 : 737 44.
10. Machado RD, Aldred MA, James V et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006 27 : 121 32.
11. Aldred MA, Machado RD, James V et al. Characterization of the BMPR2 5′-untranslated region and a novel mutation in pulmonary hypertension. Am J Respir Crit Care Med 2007 176 : 819 24.
12. Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000 37 : 741 5.
13. Newman JH, Wheeler L, Lane KB et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001 345 : 319 24.
14. Cogan JD, Vnencak-Jones CL, Phillips JA 3rd. et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 2005 7 : 169 74.
15. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005 16 : 251 63.
16. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998 9 : 49 61.
17. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000 14 : 627 44.
18. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002 296 : 1646 7.
19. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005 19 : 2783 810.
20. Rudarakanchana N, Flanagan JA, Chen H et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002 11 : 1517 25.
21. Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 2002 13 : 3055 63.
22. Yu PB, Beppu H, Kawai N et al. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem 2005 280 : 24443 50.
23. Long L, MacLean MR, Jeffery TK et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006 98 : 818 27.
24. Yang X, Long L, Southwood M et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005 96 : 1053 63.
25. Valdimarsdottir G, Goumans MJ, Rosendahl A et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002 106 : 2263 70.
26. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 2006 98 : 209 17.
27. McDonald PP, Fadok VA, Bratton D, Henson PM. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells. J Immunol 1999 163 : 6164 72.
28. McAllister KA, Grogg KM, Johnson DW et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994 8 : 345 51.
29. Johnson DW, Berg JN, Baldwin MA et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996 13 : 189 95.
30. Attisano L, Carcamo J, Ventura F et al. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993 75 : 671 80.
31. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999 274 : 584 94.
32. Trembath RC, Thomson JR, Machado RD et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001 345 : 325 34.
33. Harrison RE, Flanagan JA, Sankelo M et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003 40 : 865 71.
34. David L, Mallet C, Mazerbourg S et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007 109 : 1953 61.
35. Atkinson C, Stewart S, Upton PD et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002 105 : 1672 8.
36. Gurtner HP. Chronic pulmonary hypertension of vascular origin, plexogenic pulmonary arteriopathy and the appetite depressant aminorex: addenda to an epidemic. Schweiz Med Wochenschr 1985 115 : 782 9.
37. Humbert M, Deng Z, Simonneau G et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002 20 : 518 23.
38. Souza R, Humbert M, Sztrymf B et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008 31 : 343 8.
39. Song Y, Jones JE, Beppu H et al. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005 112 : 553 62.
40. Sztrymf B, Coulet F, Girerd B et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008 177 : 1377 83.
41. Elliott CG, Glissmeyer EW, Havlena GT et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006 113 : 2509 15.
42. McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 1 (Suppl. 14S 34S.